Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a $300K Phase I SBIR grant from the NIAID at the NIH to fund the continued advancement of the company’s proprietary PANDAA™ technology platform and its specific application to the universal, pan-lineage detection of Lassa virus, the causative agent of Lassa fever.
Aldatu Biosciences Awarded $3 Million NIH SBIR Contract for Early HIV Drug Resistance Detection
October 15th, 2018 (BOSTON, MA) — Aldatu Biosciences, an early-stage biotechnology company developing diagnostic assays for the detection of infectious diseases and antimicrobial resistance, today announced it has been awarded …
Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory Board
August 3rd, 2017 (BOSTON, MA) Aldatu Biosciences, a biotechnology company developing innovative diagnostics for complex infectious diseases on its PANDAA qDx platform, today announced the expansion of its Scientific and …
In Memory of Mark Wainberg: Aldatu Advisor and HIV Pioneer
It is with deep sadness that we pass along news of the sudden death of our friend, mentor, and Scientific Advisory Board member, Prof. Mark Wainberg. Mark was one of the earliest supporters of Aldatu and our efforts to bring PANDAA to patients, and for that he will always have our gratitude. His passing represents a tremendous loss for not only our company, but the entire HIV community. Our hearts and thoughts are with his family and colleagues today.
Aldatu Biosciences Receives $3 Million SBIR Grant to Expand PANDAA-based HIV Drug Resistance Diagnostic Development
Aldatu Biosciences has been awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant for approximately $3,000,000 over three years from the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary platform technology, PANDAA, and its specific application to HIV genotyping.
Aldatu Biosciences Secures Impact-Driven Investment as a Public Benefit Corporation
Aldatu recently received a program-related investment (PRI) from CH Innovations (a subsidiary of the Charles H. Hood Foundation), a Boston based organization whose mission is to fund entrepreneurial efforts to improve the health and quality of life for children around the world.
Aldatu Biosciences Licenses PANDAA Technology from Harvard University
Aldatu Biosciences, Inc. today announced that it has entered into a licensing agreement with Harvard University’s Office of Technology Development based on intellectual property developed in the laboratory of Professor Myron (Max) Essex, DVM, PhD, at the Harvard T.H. Chan School of Public Health.
Q&A: A New Test For Drug-Resistant HIV Breaks All the Scientific Rules
Q&A: A New Test For Drug-Resistant HIV Breaks All the Scientific Rules A former postdoctoral fellow with the Harvard T.H. Chan School of Public Health AIDS Initiative, virologist Iain MacLeod …
Aldatu Selected for AdvaMed 2015 Innovation Showcase
Washington, DC, 18th September 2015 (download press release .pdf) AdvaMed 2015: The MedTech Conference, the leading gathering of medical technology professionals in North America, has awarded 48 scholarships to early and …
Aldatu Named a 2015 RESI Innovator
Aldatu was selected to participate in the Innovation Challenge as part of the Redefining Early State Investments (RESI) Conference being held in Boston on September 16th, 2015. Aldatu will join 29 other innovative life science companies in therapeutics, diagnostics, medical devices, and healthcare IT tracks in an exhibition-style presentation format throughout the day-long conference.